Author/Authors :
MAMISHI, Setareh Pediatric Center of Excellence - Children’s Medical Center - Tehran University Medical Science - Tehran, Iran , ASHRAFI, Mahmoud Reza Pediatric Center of Excellence - Children’s Medical Center - Tehran University Medical Science - Tehran, Iran , MOHAMMADI, Mahmoud Pediatric Center of Excellence - Children’s Medical Center - Tehran University Medical Science - Tehran, Iran , ZAMANI, Gholamreza Pediatric Center of Excellence - Children’s Medical Center - Tehran University Medical Science - Tehran, Iran , POURAKBARI, Babak Pediatric infectious Research Center - Tehran University Medical Science - Tehran, Iran , MAHMOUDI, Shima Pediatric infectious Research Center - Tehran University Medical Science - Tehran, Iran , AZIZ-AHARI, Solmaz Pediatric Center of Excellence - Children’s Medical Center - Tehran University Medical Science - Tehran, Iran
Abstract :
Guillain-Barré syndrome (GBS) is an immune-mediated disease of the
peripheral nervous system affecting all age groups around the world.
Although the pathogenesis and optimal treatment of GBS have not
yet been completely identified, one of the most common infectious
diseases to trigger the syndrome is cytomegalovirus (CMV) infection.
The GBS following CMV infection is rarely reported in childhood,
and there have been no data on GBS with antecedent CMV infection
in children in Iran. The current study aimed to evaluate the association
between CMV infection and GBS in children in Iran.
Materials & Methods
The case-control study design was used for 30 GBS cases and 30
matched controls. All the serum samples were tested for the presence
of anti-CMV immunoglobulin M (IgM) and immunoglobulin G
(IgG) antibodies using a commercially available enzyme-linked
immunosorbent assay (EUROIMMUN Medizinische, Germany).
The CMV viral deoxyribonucleic acid (DNA) in the specimen was
detected using polymerase chain reaction (PCR) (Cytomegalovirus
PCR Detection Kit, CinnaGen Co., Iran).
Results
Anti-CMV IgG antibodies were detected in 97% of the GBS patients
and 93% of the healthy controls. Anti-CMV IgM antibodies were
demonstrated in 33% of the healthy controls (n=10) and 33% of
the GBS children (n=10). The borderline level of anti-CMV IgM
antibodies was observed in 23% of the healthy controls (n=7) and 13%
of the GBS children (n=4) (P=0.57). None of the specimens from both controls and GBS cases was positive for CMV DNA using PCR.
Conclusion
The obtained data demonstrated the presence of anti-CMV antibodies
in the majority of both GBS patients and controls. Moreover, no
relation was observed between CMV infection and GBS. However,
it is highly recommended to perform further studies with a large
sample size.